Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statement Detail (Details)

v2.4.0.6
Condensed Consolidated Financial Statement Detail (Details)
3 Months Ended 6 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2012
USD ($)
Jun. 30, 2011
Jun. 30, 2012
USD ($)
Jun. 30, 2011
Dec. 31, 2011
USD ($)
Jun. 30, 2012
Five year warrants issued in February 2010 [Member]
USD ($)
Dec. 31, 2011
Five year warrants issued in February 2010 [Member]
USD ($)
Feb. 28, 2010
Five year warrants issued in February 2010 [Member]
USD ($)
Jun. 30, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
Jun. 30, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
Mar. 31, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
Mar. 01, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
Jun. 30, 2012
Warrants issued to private investors [Member]
USD ($)
Dec. 31, 2011
Warrants issued to private investors [Member]
USD ($)
Jun. 30, 2010
Warrants issued to private investors [Member]
Jun. 30, 2009
Warrants issued to private investors [Member]
USD ($)
Jun. 30, 2012
Options Contract [Member]
USD ($)
Jun. 30, 2012
Options Contract [Member]
USD ($)
Jun. 30, 2012
Options Contract [Member]
EUR (€)
Jan. 31, 2016
Options Contract [Member]
EUR (€)
Jan. 31, 2014
Options Contract [Member]
EUR (€)
Jun. 30, 2012
Common stock options and restricted stock units [Member]
Jun. 30, 2011
Common stock options and restricted stock units [Member]
Jun. 30, 2012
Common stock options and restricted stock units [Member]
Jun. 30, 2011
Common stock options and restricted stock units [Member]
Jun. 30, 2012
Convertible preferred stock [Member]
Jun. 30, 2011
Convertible preferred stock [Member]
Jun. 30, 2012
Convertible preferred stock [Member]
Jun. 30, 2011
Convertible preferred stock [Member]
Jun. 30, 2012
Warrants for common stock [Member]
Jun. 30, 2011
Warrants for common stock [Member]
Jun. 30, 2012
Warrants for common stock [Member]
Jun. 30, 2011
Warrants for common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                                                                  
Antidilutive securities excluded from computation of earnings per share (in shares) 21,823,000 5,457,000 16,645,000 5,453,000                                   5,121,000 3,833,000 5,566,000 3,711,000 0 17,000 0 135,000 16,702,000 1,607,000 11,079,000 1,607,000
Cash and cash equivalents [Abstract]                                                                  
Demand deposit $ 9,900,000   $ 9,900,000   $ 21,100,000                                                        
Money market funds 30,000,000   30,000,000   27,200,000                                                        
U.S. treasury securities 15,000,000   15,000,000                                                            
Short-term Investments [Abstract]                                                                  
Short-term investments, U.S. treasury securities 11,993,000   11,993,000   0                                                        
Derivative [Line Items]                                                                  
Derivative, amount of hedged item                                       15,000,000 1,500,000                        
Number of foreign exchange option contracts                                 2 2 2                            
Derivative, premiums                                   1,500,000                              
Derivative fair value                                 600,000 600,000                              
Derivative, loss                                 300,000 600,000                              
Debt and accrued interest payments in Euros                                     15,000,000                            
Accrued liabilities [Abstract]                                                                  
Accrued payroll and other benefits 2,306,000   2,306,000   3,007,000                                                        
Accrued management incentive compensation 1,894,000   1,894,000   4,096,000                                                        
Accrued clinical trial costs 1,927,000   1,927,000   140,000                                                        
Accrued severance payments 403,000   403,000   1,207,000                                                        
Other 1,336,000   1,336,000   1,562,000                                                        
Total 7,866,000   7,866,000   10,012,000 [1]                                                        
Class of Warrant or Right [Line Items]                                                                  
Warrants outstanding (in shares)               1,260,000 14,829,167     14,834,577     347,826                                    
Exercise price (in dollars per share) $ 1.76   $ 1.76         $ 10.5       $ 1.76       $ 19.5                                  
Fair value of warrant liability             300,000   23,300,000 23,300,000 6,400,000     100,000                                      
Gain (loss) on revaluation of warrant liability           $ 300,000     $ (2,200,000) $ (16,900,000)     $ 100,000                                        
Warrants outstanding (in shares) 14,834,577   14,834,577         1,260,000       14,834,577     347,826                                    
[1] The condensed consolidated balance sheet as of December 31, 2011 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011.